News

UVA teaming up with Charlottesville pharmaceutical company for new burn treatment

CHARLOTTESVILLE, Va. (WVIR) – The University of Virginia School of Medicine is teaming up with a Charlottesville company to create a new burn treatment.

Typically when skin is burned, the area surrounding it is impacted and dead, too. This new treatment is a cream that is put directly on severe wounds.

“Our hope is that by doing this, we can actually limit the amount of skin grafts people have to get and be able to treat especially like warfighters,” Doctor Mark Roeser said.

Roeser says the idea behind the drug comes from a type oflung treatment that is usually given in an IV. That form, however, is not convenient to treat burns.

“The time of injury is obviously the part of when you want to get the medication on you,” Roeser said. “So if it’s in a cream form, we can apply it more rapidly.”

Roeser is working with Charlottesville-based pharmaceutical company, Purnovate, which is a subsidiary of Adial, to make that happen.

“We’ve already done work to determine that our drugs seem to work well in skin penetration,” Adial CEO William Stilley said.

Stilley says his company has a history of working with UVA, which is why he and Roeser are taking this next step together.

“He’s going to take our molecules, put them into a cream, and then use them use that to try to develop something that would help him promote healing,” Stilley said.

“This will keep the burns limited to only the part, or at least try to limit to only the part that’s injured and not the part that your body enters either accidentally, or for whatever reason your body does that,” Roeser said.

The cream is supposed to reduce inflammation on burns.

“So much of the body’s damage can be caused by inflammation,” Stilley said. “And if we can have a good anti-inflammatory, there’s a number of different important diseases we can really help.”
The teams think if this works, it could be applied to other wounds, and be used in places where quick treatment counts, like war zones.

Read more here.

Recent News

02/20/2025

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

“Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return

02/11/2025

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,  announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration seeks to develop the first intranasal therapy for mild traumatic brain injury (mTBI) aka concussion, creating a comprehensive trigger-to-treat

02/11/2025

Children’s National and Compremium partner on pediatric medtech innovation

Children’s National Hospital announced a new collaboration with Swiss medical device company Compremium AG to co-develop and commercialize innovative medical technologies designed specifically for pediatric patients. This first-of-its-kind agreement leverages the expertise of Children’s National in pediatric healthcare innovation and Compremium’s non-invasive platform technology for diagnosing pressure-related conditions, accelerating advancements in pediatric medicine. Diagnosing pressure-related